Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 02 December 2013 | By Alexander Gaffney, RAC,
Does the US Food and Drug Administration (FDA) have some big changes in the works for the way in which it regulates drug advertising? A review of a slew of studies the agency has proposed in the last two years indicates that maybe-just maybe-it is.
Since 2012, FDA has proposed a torrent of studies targeting niche aspects of the way in which drug promotional activities, and especially TV-based advertising aimed at consumers, are regulated.
A brief overview of those studies is as follows:
Taken together, the proposed studies could indicate coming changes in FDA's regulatory approach toward advertising, presumably wide in scope but targeted in effect. One can assume that FDA isn't in the habit of spending money on studies just to satisfy its curiosity; rather, the studies are presumably to validate a hypothesis with the unstated intent of informing future regulatory actions.
The proposed and ongoing studies are also relatively unique in one respect: We can recall no other area that has been subject to even a single proposed behavioral study that is not related to drug advertising.
In other words, this might be one area worth keeping a close eye on.
Tags: OPDP
Regulatory Focus newsletters
All the biggest regulatory news and happenings.